Trial Profile
Tolerability of the intravenous immunoglobulin Octagam® 10%
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2017
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions
- Sponsors Octapharma
- 05 Nov 2016 New trial record
- 01 Nov 2016 Results assessing safety and tolerability using data from this and other three trials published in the International Journal of Clinical Pharmacology and Therapeutics.
- 10 Oct 2016 Results assessing safety and tolerability using data from this and other three trials published in the International Journal of Clinical Pharmacology and Therapeutics